ArticleResuscitation plus2026
Serial plasma proenkephalin A 119-159 and dipeptidyl peptidase 3 after cardiac arrest: association with long-term neurological outcome.
Article in Resuscitation plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate whether serial plasma proenkephalin A 119-159 (penKid) and circulating dipeptidyl peptidase 3 (cDPP3) after cardiac arrest are associated with long-term neurological outcome and mortality.
methodsWe performed a retrospective multicentre cohort study of adults admitted to intensive care after cardiac arrest in southern Sweden. Biomarkers were measured on admission and at 12 and 48 h. The primary outcome was poor neurological outcome, defined as Cerebral Performance Category 3-5 at 2-6 months. The secondary outcome was 180-day mortality. Models were adjusted for established
resultsAmong 417 patients, 271 (65%) had poor neurological outcome and 266 (64%) died within 180 days. PenKid was independently associated with poor neurological outcome at admission (adjusted odds ratio 1.62, 95% confidence interval 1.15-2.28) and 12 h (1.50, 1.08-2.09), and with mortality at admission (adjusted hazard ratio 1.36, 1.20-1.54) and 12 h (1.33, 1.17-1.51). cDPP3 was independently associated with mortality at 12 h (1.26, 1.11-1.43), but not with poor neurological outcome after adjustment. Neither biomarker significantly improved discrimination beyond the clinical reference model.
conclusionsEarly penKid was associated with poor neurological outcome and mortality after cardiac arrest, whereas cDPP3 was associated with mortality at 12 h. These biomarkers added limited discriminatory value beyond established clinical predictors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.